Given its ability to elevate insulin levels, inhibit glucagon secretion, and slow the digestive process via modulating the GLP-1 signaling pathway, semaglutide began to be manufactured by Novo Nordisk [2] and was approved first as a subcutaneous injection (Ozempic®) and then as an oral tablet (Rebylsus®) for glycemic control in adults with T2DM [3,4]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.